Related Experiment Video

Updated: Aug 22, 2026

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Monoclonal antibodies in cancer therapy

Barbara Gatto1

  • 1Department of Pharmaceutical Sciences, University of Padova, via Marzolo 5, 35131 Padova. barbara.gatto@unipd.it

Current Medicinal Chemistry. Anti-Cancer Agents
|September 24, 2004
PubMed

Insights

Biotech investment in monoclonal antibodies (Mabs) for cancer is growing, with new chimeric, humanized, and fully human Mabs in development. These advancements aim to optimize Mabs for treating solid tumors.

Area of Science:

  • Biotechnology
  • Oncology
  • Immunotherapy

Background:

  • Recent FDA approvals of monoclonal antibodies (Mabs) like cetuximab and bevacizumab for metastatic colorectal cancer highlight significant biotech investment.
  • Market analyses indicate substantial growth in therapeutic Mabs, with further expansion projected due to ongoing clinical trials.

Purpose of the Study:

  • To review the current landscape and future prospects of monoclonal antibodies in cancer therapeutics.
  • To highlight advancements in Mab production technologies and their impact on drug development pipelines.

Main Methods:

  • Analysis of market trends and clinical trial data for therapeutic monoclonal antibodies.
  • Review of technological advancements in Mab production, including chimeric, humanized, and fully human antibody development.

Main Results:

  • The pipeline includes an increasing number of chimeric, humanized, and fully human Mabs.
  • Technological improvements are addressing limitations in Mab production.
  • Understanding of antibody mechanisms enables optimization for solid tumors.

Conclusions:

  • Monoclonal antibodies represent a rapidly expanding area of cancer therapeutics.
  • Ongoing research and technological innovation are driving the development of more effective and targeted Mab therapies.
  • Optimized Mabs hold promise for treating high-incidence solid tumors.

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...